1st commercialized solution2 that compensates for involuntary respiratory motion artifacts on Interventional CBCT.
Physicians estimate that up to 40%3 of CBCT acquisitions are unusable due to involuntary respiratory motion artifacts.
In up to 25%3 of CBCT images affected by involuntary respiratory motion, Motion Freeze, by potentially reducing the need to repeat CBCT acquisitions, may help minimize radiation dose and contrast media injection.
39% (1.9 billion) of the world adult population is overweight (BMI<25) or obese.4 These patients may have more difficulties holding their breath during the intervention. Motion Freeze provides an additional option for physicians to use CBCT even if they are affected by involuntary respiratory motion artifacts.
Facilitate access to advanced solutions such as FlightPlan for Liver, delivering results up to: 97% improved sensitivity in identifying tumor feeding vessels, 30% less mean number of DSA, 11% reduction in procedure time for a single TACE session5 and ~68% complete tumor response versus DSA alone (36%)6 .
*The improvement related to Motion Freeze depends on the acquisition conditions, table position, patient, type of motion, anatomical location and clinical
practice. Motion Freeze is an optional feature of 3DXR (part of GE vascular systems IGS 5, IGS 6 and IGS 7 or IGS 7OR). 3DXR cannot be placed on the
market or put into service until it has been made to comply with all required regulatory authorizations including the Medical Device Directive requirements
for CE marking. Motion Freeze cannot be marketed in countries where market authorization is required and not yet obtained. Refer to your sales representative.
2. Based on competitive research, among major players in interventional imaging
3. Based on the quantitative assessment of 6 recognized Interventional Radiologists specialized in the field of Interventional Oncology, using various intervention angiography systems from different vendors.
4. World’s Health Organization data “Global Database on Body Mass Index” & World’s Health Organization: “Obesity andoverweight Fact sheet N°311 Updated January 2015”
6. 2 Cornelis et al, Hepatic Arterial Embolization Using Cone Beam CT with Tumor Feeding Vessel Detection Software: Impact on Hepatocellular Carcinoma Response, CVIR 2017
7. Iwazawa, J., Ohue, S., Hashimoto, N., Muramoto, O., and Mitani, T. (2013). Clinical utility and limitations of tumor-feeder detection software for liver cancer embolization. Eur. J. Radiol. 82, 1665–1671.